Rescue Hearing — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Rescue Hearing is a private, preclinical-stage biotech focused on developing curative gene therapies for genetic hearing loss, a condition affecting over 466 million people globally with no approved restorative treatments. The company's pipeline targets specific mutations (DFNB8, DFNB16, USH1B) and leverages a partnership with Myrtelle for its lead DFNB8 program. Led by a CEO with a personal connection to the mission and a CSO who pioneered the first gene therapy for hearing loss to enter human trials, Rescue Hearing aims to address a significant unmet medical need through targeted genetic intervention.

Genetic Hearing LossUsher Syndrome

Technology Platform

Gene therapy platform utilizing viral vectors (likely AAV) for targeted delivery of functional genes to the inner ear (cochlea) to correct genetic mutations causing progressive hearing loss, combined with molecular diagnostics.

Opportunities

The primary opportunity is addressing a massive, completely untreated market of over 466 million people with hearing loss.

Success in genetic subsets can establish a regulatory pathway and proof-of-concept for broader applications, potentially creating an entirely new therapeutic category in otology.

Risk Factors

Key risks include the unproven clinical efficacy and safety of inner ear gene therapy, the nascent and uncertain regulatory pathway for hearing restoration endpoints, and the significant funding required to advance multiple preclinical programs.

Commercial challenges include high therapy costs and reimbursement hurdles in a market accustomed to devices.

Competitive Landscape

The competitive landscape is nascent but growing. While there are no approved gene therapies for hearing loss, several academic groups and biotechs (e.g., Akouos, Decibel Therapeutics, Frequency Therapeutics) have been active, though some have faced clinical setbacks. Rescue Hearing's focused approach on specific genetic forms and its partnership with Myrtelle provide a differentiated strategy in this emerging field.

More companies in Cell & Gene Therapy →More companies in United States →